MIM
DOVA

MetLife Investment Management’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

MetLife Investment Management’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,038
Closed -$127K – 2623
2018
Q3 		$127K Hold
6,038
– – ﹤0.01% 2323
2018
Q2 		$181K Buy
+6,038
New +$164K ﹤0.01% 1967

Other funds holding DOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MetLife Investment Management's DOVA Position: Q4 2018 in Review

MetLife Investment Management sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2018, closing a stake of 6,038 shares — an estimated $127K sold.

MetLife Investment Management first reported a position in DOVA in Q2 2018 and held it in 2 quarters. The position peaked at $181K in Q2 2018. 58 funds tracked by Wall St. Rank hold DOVA as of Q4 2018.

  • MetLife Investment Management reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • MetLife Investment Management sold 6,038 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $127K.
  • MetLife Investment Management first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • MetLife Investment Management's Dova Pharmaceuticals, Inc. Common Stock position peaked at $181K in Q2 2018.
  • 58 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on MetLife Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.